Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

Sonelokimab, adalimumab, lutikizumab, and bimekizumab are the top-rated treatments for moderate-to-severe HS, a network ...

A slew of biosimilar versions of TNF-alpha inhibitor adalimumab will finally arrive on the U.S. market in 2023, almost seven years after the first such molecule, Amgen Inc.’s Amjevita (adalimumab-atto ...

What we see with the adalimumab biosimilars, the key pivotal trials have been conducted mainly in rheumatoid arthritis and/or psoriasis. These are indications where you have 2 different indications.

Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and Bioventure. Alvotech and Bioventure, a wholly owned subsidiary of ...

Patients were randomly assigned to continue adalimumab, which was administered subcutaneously every 2 weeks in weight-adjusted doses (n = 43; mean age, 12.56 years; 74% girls), or to discontinue ...

Another Adalimumab Biosimilar Seems Set for Interchangeability — Trial data pave way for FDA approval by John Gever , Contributing Writer, MedPage Today November 14, 2022 • 4 min read ...

Use of methotrexate with adalimumab was associated with increased recurrence risk (HR 2.1, 95% CI 1.07-4.10) in univariate analysis. This was the only factor examined in the study, ...

Pariser DM, Lebwohl MG, Jaworski J, et al. CT-P17 adalimumab biosimilar in patients with moderate-to-severe chronic plaque psoriasis: An open-label extension of a phase 3 interchangeability study.

In a meta-analysis of two clinical trials of adalimumab, 22,23 the difference in the percentage of patients with a DAS28-CRP of less than 3.2 at week 12 between adalimumab plus methotrexate (537 ...

During the controlled portions of 39 global adalimumab clinical trials in adult patients with RA, PsA, AS, CD, UC, PS, HS and UV, the rate (95% confidence interval) of NMSC was 0.8 (0.52, 1.09 ...

A preview of the next edition of BioWorld, Feb. 22, 2023. A slew of biosimilar versions of the TNF-alpha inhibitor adalimumab will finally arrive on the U.S. market in 2023, almost seven years after ...